Cempra (CEMP) announces its intention to launch a public offering. The proceeds from the...

|By:, SA News Editor

Cempra (CEMP) announces its intention to launch a public offering. The proceeds from the potential deal will go towards the "Phase 3 clinical trial of solithromycin in community acquired bacterial pneumonia." In a separate PR, CEMP described the steps it will need to take to get the treatment approved.